PROSCA/BLADDR 2020 | Genomic testing in prostate cancer

Emmanuel Seront, MD, PhD, Jolimont Hospital, La Louvière, Belgium, outlines the use of genomic testing in prostate cancer as well as abnormalities seen in these patients that influence prognosis including BRCA mutated patients that can be targeted using olaparib. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).